1,2,3,4,4a,9b-Hexahydro-5H-indeno<1,2-c>pyridin | 24189-14-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 1,2,3,4,4a,9b-Hexahydro-5H-indeno<1,2-c>pyridin
• 英文别名: 2,3,4,4a,5,9b-hexahydro-1H-indeno[1,2-c]pyridine
• CAS: 24189-14-8
• 化学式: C₁₂H₁₅N
• 分子量: 173.258
• InChiKey: DKXPREDBWUTBBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• IMIDAZO[1',2':1,6]PYRIDO[2,3-D]PYRIMIDINE COMPOUND AS PROTEIN KINASE INHIBITOR
  申请人：SHENGKE PHARMACEUTICALS (JIANGSU) LTD.

  公开号：US20200270251A1

  公开（公告）日：2020-08-27

  Provided is an imidazo[1′;2′:1,6]pyrido[2,3-d]pyrimidine compound of general formula (I). The compound can be used in treating a cell proliferative disorder and is a cyclin-dependent kinase (CDK) inhibitor with broad-spectrum and strong activity.

  提供的是一种通式为(I)的咪唑[1′;2′:1,6]吡啶[2,3-d]嘧啶化合物。该化合物可用于治疗细胞增殖紊乱，是一种具有广谱和强活性的周期蛋白依赖性激酶（CDK）抑制剂。
• LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT
  申请人：Georg Ingrid Gunda

  公开号：US20110060003A1

  公开（公告）日：2011-03-10

  Fertility management can include: administering to the subject one or more doses of a compound according to Formula I so as to reduce fertility in the subject. Fertility management can also include administering an effective amount of the compound to: impair Sertoli cell function in a male subject; inhibit spermatogenesis in the subject; reduce testis weight in the subject; reduce ovary weight in a female subject; reduce serum progesterone in the female subject; impair ovarian follicle function in the female subject; causing reversible fertility in the subject. In order to return fertility, the method can include ceasing administration of the compound to the subject so as to return fertility in the subject. The compound can be administered for irreversibly sterilizing the subject.

  生育管理可以包括：根据公式I的一个或多个剂量给予受试者一种化合物，以降低受试者的生育能力。生育管理还可以包括给予化合物的有效量：破坏雄性受试者的精原细胞功能；抑制受试者的精子生成；减少受试者的睾丸重量；减少雌性受试者的卵巢重量；减少雌性受试者的血清孕酮；破坏雌性受试者的卵巢滤泡功能；导致受试者可逆的生育能力。为了恢复生育能力，该方法可以包括停止给予化合物以使受试者恢复生育能力。该化合物可以用于对受试者进行不可逆的绝育。
• (3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-acetic acid derivatives and related tricyclic indanyls as alphaVbeta3 and alphaVbeta5 integrin inhibitors for the treatment of cancer and unstable angina
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1506779A1

  公开（公告）日：2005-02-16

  The present invention is directed to substituted indanyl compounds of Formula (I): useful for treating integrin-mediated disorders such as, but not limited to unstable angina, thromboemboic disorders, osteoporosis, growth and metastasis of malignant tumors, diabetic retinopathy, arthritis, viral disease and surgical adhesions. The substituents are defined in claim 1.

  本发明涉及式（I）的取代茚满化合物： 用于治疗整合素介导的疾病，如但不限于不稳定型心绞痛、血栓性疾病、骨质疏松症、恶性肿瘤的生长和转移、糖尿病视网膜病变、关节炎、病毒性疾病和手术粘连。 取代基定义见权利要求 1。
• 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR
  申请人：Shengke Pharmaceuticals (Jiangsu) Ltd.

  公开号：EP3608321A1

  公开（公告）日：2020-02-12

  Provided is a 1H-imidazo[4,5-h]quinazoline compound of formula (I). The compound is a broad spectrum inhibitor having strong activity for cyclin-dependent kinase (CDK) and is applicable in treating cell proliferative disorder

  本文提供了一种式（I）的 1H-咪唑并[4,5-h]喹唑啉化合物。 该化合物是一种广谱抑制剂，对依赖细胞周期蛋白的激酶（CDK）具有很强的活性，适用于治疗细胞增殖性疾病。
• Imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidine compound as protein kinase inhibitor
  申请人：SHENGKE PHARMACEUTICALS (JIANGSU) LTD.

  公开号：US11091485B2

  公开（公告）日：2021-08-17

  Provided is an imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidine compound of general formula (I). The compound can be used in treating a cell proliferative disorder and is a cyclin-dependent kinase (CDK) inhibitor with broad-spectrum and strong activity.

  本文提供了一种通式（I）的咪唑并[1′,2′:1,6]吡啶并[2,3-d]嘧啶化合物。该化合物可用于治疗细胞增殖性疾病，是一种具有广谱和强活性的细胞周期蛋白依赖性激酶（CDK）抑制剂。